NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

November 30, 2025

Conditions

Advanced or Metastatic Solid TumorsMicrosatellite Instability LowMicrosatellite Instability HighMicrosatellite StableOvarian CancerGastric CancerColo-rectal CancerEsophageal CancerEndometrial CancerHead Neck CancerCervical CancerLung Cancer

Interventions

DRUG

NC410

NC410 will be given intravenously (IV) every 2 weeks

DRUG

pembrolizumab

Pembrolizumab 400mg will be given IV every 6 weeks.

Trial Locations (17)

10016

NYU Langone Health, New York

14203

Roswell Park Comprehensive Cancer Center, Buffalo

21231

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

22031

Inova Schar Cancer Institute, Fairfax

Virginia Cancer Specialist, Fairfax

41017

St. Elizabeth Edgewood Hospital, Edgewood

45267

University of Cincinnati Cancer Center, Cincinnati

70121

Ochsner Cancer Institute, New Orleans

75235

UT Southwestern Medical Center, Dallas

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

77030

MD Anderson Cancer Center, Houston

78229

UT Health San Antonio, San Antonio

78240

Texas Oncology - San Antonio, San Antonio

80012

Rocky Mountain Cancer Centers, Aurora

85711

Arizona Oncology Associates, Tucson

98684

Northwest Cancer Specialist, Vancouver

07601

Hackensack Meridian Health University Medical Center- John Theurer Cancer Center, Hackensack